TORONTO, Jan. 28 /CNW/ - LivDerma's Dr. Joseph Gabriele has developed a
unique, evidence-based transdermal delivery system to enter deep into
the skin's dermis that produces strong pharmalogical effects. DELIVRA™ represents a new paradigm of transdermal healing, encouraging both
pharma-based and organic remedies to be transported, with precision
effect, to ailing sites in deep-lying muscular tissues and joints,
thereby avoiding drug conflicts and side effects. LivRelief™ is making history through its influence to revolutionize the therapeutic
pain relief category. Canadians are among the first to benefit from its
Every year, millions Canadians are in pain. This agonizing statistic is
on the rise, with the age of affliction getting younger and younger. We
are a nation in overwhelming pain and as a result have far too many
over medicating, unable to tolerate ingestible remedies and many more
who are getting secondary health conditions as a result of attempting
to manage their pain.
LivRelief™ has been proven to reduce pain and inflammation more effectively than
the leading topical brands by blocking five key pain pathways. While leading brands block one or two, LivRelief™ is derived of natural ingredients and does not contain any synthetic
drugs. It is natural, paraben free, sodium laurel sulfate free and has
not been tested on animals.
Unlike pills that pass through major organs and can cause stomach upset,
cardiovascular problems and a host of other health issues, LivRelief™ delivers fast, effective relief through the skin, directly to the painful muscle or joint by way of DELIVRA™.
Through a personal pursuit of trying to achieve pain relief for his wife
who became ill LivDerma founder Gabriele comments "The initial results
have been both compelling and remarkable; clearly showing significant
pain relief at the local level without the use of synthetic
pharmacological drugs. We have now completed a double blind crossover
parallel study on joint pain suffers along with a prospective study
with significant results for knee pain."
CLINICAL STUDIES: Early clinical testing of DELIVRA™ has yielded impressive results. A double-blind crossover study,
conducted in mid-2009, shows that after 6 weeks of using the LivDerma
pain cream with DELIVRA™, 70 sufferers found their pain reduced by half, and their mobility and
quality of life enhance by more than 59%. An independent laboratory is
currently conducting in vitro penetration studies to identify exactly
how deep DELIVRA™ reaches, and exactly what quantity of companion substances are delivered
to sub dermal sites. In these studies, DELIVRA™ performance is measured against that of Pluronic Lecithin Organogel
(PLO), a pharma base that is partly synthetic, and the worlds most
widely used compounding base. Both the scientific and anecdotal
evidence is compelling.
For product samples, copies of scientific data or to arrange a time to
speak with Dr Gabriele:
For further information:
The Marquis Group for LivDerma